VIVO CAPITAL, LLC
VIVO CAPITAL, LLC is a Seed, Series A, Series B, Series C+, buyout and other fund in the US, Global, China and Singapore investing in Healthcare, biotechnology, medical-devices, pharmaceuticals and life-sciences.
- Stages
- Seed, Series A, Series B, Series C+, buyout, other
- Sectors
- Healthcare, biotechnology, medical-devices, pharmaceuticals, life-sciences
- Invests in
- US-wide, Global, China, Singapore
- Actively investing
- Yes
- Founded
- 1996
- Assets under management
- >$7.5B
Check size not disclosed
Thesis
Vivo Capital is a global investment firm founded in 1996, specializing in the healthcare and biotechnology sectors. It operates a multi-strategy platform including venture capital, private equity, and public equity, aiming to support companies developing innovative treatments and medical technologies. Historically, 70% of capital went to biotechnology and 30% to medical devices. While initially focused on early-stage, Vivo now targets growth-stage companies and buyout deals. The Vivo Innovation Fund supports venture-stage companies, the private equity strategy focuses on scale-up, and the growth capital strategy provides funding for commercial acceleration. The Vivo Opportunity Fund invests in global public equities of small and mid-cap healthcare companies via various financing structures. As of March 2026, its total AUM exceeded $7.5 billion, with its public market fund raising $740 million. Specific check size details are not available. Headquarters are in Palo Alto, California.
Common questions
Does VIVO CAPITAL, LLC invest at the Seed stage?
Yes. VIVO CAPITAL, LLC lists Seed, Series A, Series B, Series C+, buyout and other among the stages it invests in.
Where does VIVO CAPITAL, LLC invest?
VIVO CAPITAL, LLC invests in the US, Global, China and Singapore.